Tumor angiogenic switch determines sustained proliferative malignant transformation in tumorigenesis and overlaps with para-inflammatory phenomena by Agius, Lawrence M.
Journal of Applied Medical Sciences, vol. 4, no. 4, 2015, 31-36 
ISSN: 2241-2328 (print version), 2241-2336 (online) 
Scienpress Ltd, 2015
Tumor Angiogenic Switch Determines Sustained 
Proliferative Malignant Transformation in Tumorigenesis 
and Overlaps with Para-inflammatory Phenomena 
Lawrence M. Agius1 
Abstract 
Both inflammation and tumorigenesis are analogous counterpart phenomena in overlap 
dynamics determining angiogenesis within reactive microenvironments and as angiogenic 
switch in tumorigenic expansion and progression.  In this regard, the counter-effects of 
pro-angiogenesis and of anti-angiogenesis reconstitute a series of endothelial cell 
activation steps or apoptosis of these cells.  In close parallel, apoptosis of endothelial 
cells in response to inhibitory angiogenic factors may reflect in some measure apoptosis 
of tumor cells related to such sprouting endothelial cell tubes.  Further to such measures, 
multi-potent bone marrow mesenchymal cells induce a plethora of effects relative to the 
migrating endothelial progenitor cells in terms of the ongoing promotion of angiogenesis 
and of the angiogenic switch.  Indeed, angiogenesis of tumors may prove a central 
modulator in emergence of malignant potentialities in tumorigenic lesions. 
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1  Introduction 
Tumor Angiogenesis refers to the pre-existence of host blood vessels in the first instance 
in a manner that specifically implicates the sprouting of neo-vessels within an avascular 
and hence hypoxic micro-deposit tumor of tumor cells. Angiogenesis-modulating proteins 
are ideal biomarkers for studying tumor pathophysiology [1]. It is the breakdown of the 
basement membrane of such host pre-existent vessels that is determinant, in critical 
manner, to the subsequent migration of proliferating endothelial cells, endothelial 
progenitor cells, hematopoietic multi-potent progenitor cells and also the infiltration by 
macrophages of the extracellular matrix. 
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HYPOXIA 
Particular influences exerted by the evolving hypoxia and concurrent stimulation of 
hypoxia-inducible factor-alpha1, within the essential extra-cellular tumor matrix, act as 
powerful inducers to a whole concerted series of responsive elements, including in 
particular the paracrine stimulating effects of vascular endothelial growth factor (VEGF), 
and also of basic fibroblast growth factor, and of placental inhibitor factor and of 
platelet-derived growth factor.   
 
ANGIOGENESIS 
The central stage phenomena of pro-angiogenic and anti-angiogenic system actions 
clearly delineate a highly dynamic series of pathway effects that promote both 
upregulation and downregulation of agonist effects in terms of endothelial proliferation 
and migration.  miR-125a regulates the paracrine of VEGF-A in gastric cancer and 
thereby controls angiogenesis of the tumor [2].  Selectin E, which is a leukocyte 
adhesion molecule, also calls into operation an essential series of chemotactic influences 
that particular in essential ways towards the establishment of sprouting of neovessels 
within angiogenic switch evolution of the nascent micro-tumor. 
 
Performance patterning and organizational biology in the progression of tumor 
angiogenesis is a dysfunctional attribute of the production of vascular growth factors 
involving especially production of vascular endothelial growth factor by endothelial cells 
and also by stromal fibroblasts in particular.  Benzyl butyl phthalate adversely influences 
the efficacy of chemotherapy by remodeling the tumor microenvironment of breast cancer 
[3].  
 
PROTEASE ACTIONS 
Protease degradation of the extracellular matrix, on the one hand, and of the vascular 
basement membrane is itself a requisite and critical determinant in angiogenic patterning 
in tumor evolution.  The use of bevacizumab to reduce angiogenesis improves clinical 
outcome in colorectal cancer [4].  Metalloproteinase 2 and 9 in particular contribute to 
possible emergence of endothelial cell migration from the pre-existing vessels, 
particularly with reference to the capillary-venous interface.  Visualization of abnormal 
vascular tortuosity may render possible a better understanding of changes in the vascular 
microenvironment during tumor progression [5].  In such manner, also, degradation of 
the extracellular matrix progresses concurrently with the protease-induced degradation of 
the vascular basement membrane within shifting systems of enhanced angiogenesis.  
Such a phenomenon is also partly regulated by protease-induced liberation of vascular 
endothelial growth factor that is bound to matrix proteins.   
 
INHIBITORY PATHWAYS 
Further to such progression, a series of inhibitory pathways operate to better orchestrate 
the angiogenesis phenomenon.  The cleavage in particular of collagen IV, which is the 
most abundant component of the vascular endothelial basement membrane, creates 
various domain residues with potential anti-angiogenic effects.  Thus endostatin and 
tumstatin have significant anti-angiogenic action and are derived from the cytoplasmic 
globular terminal of the non-collagenous domain of the collagen type XVIII molecule. 
Endostatin action is significant particularly in view of the direct inhibition of expression 
of VEGF and of vascular permeability. 
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Pattern formulation in tumor angiogenesis is dominantly influenced by “outside-inside” 
and “inside-outside” signaling induced by integrin receptors, in particular, by molecules 
alphav-beta3 and alphav-beta5 integrins.  Antibodies against alphav-beta3 on endothelial 
cells inhibit binding to basic fibroblast growth factor, whereas antibodies to alphav-beta5 
integrin inhibit binding to VEGF. 
Also, particular significant are the interactions of integrin molecules with extracellular 
matrix, and they play an essential role in the migration of activated endothelial cells in 
angiogenic sprouting, 
The creation of soluble receptor factions such as the VEGF-2 receptor flk-1 has also been 
found to operate as powerful inhibitors in angiogenesis. 
 
RECONSTRUCTIVE OPERABILITY 
Dimensional reconstruction of operability implicate an overall patterning formulation that 
is integral to the evolving tumor angiogenic process in a specific manner inducing the 
cooperative institution of arrays of proliferating or partly hypoxic tumor cells in 
association with the sprouting endothelial cell tubes.  It is significant to recognize 
hypoxic effects that are indeed powerful stimulants in the paracrine production of VEGF 
by both endothelial cells and tumor cells.  Hypoxia-inducible factor 1 promotes the 
initiation, progression, metastasis and resistance to treatment of the majority of solid 
tumors [6]. 
The vascular basement membrane and also integral tissue components, which include 
extracellular matrix components, hence cooperatively determine dominant positive and 
dominant negative pathway effects in the migration, proliferation of endothelial cells and 
in the formation of endothelial cell tubes.  In this regard, the subsequent deposition of a 
basement membrane to the spouting endothelial cell tubes establishes maturation 
attributes to the tumor cell bed in a manner that may also allow enhanced permeability in 
regions of this vascular bed. 
 
EMBRYONIC VASCULARIZATION PARALLELS 
It is especially significant to recognize essential parallel formulations of vascular growth 
factor actions in tumor vascular beds with the embryonic process of vasculogenesis early 
in development.  Bone marrow mesenchymal cells that are pluripotent cell elements play 
a vital process in embryonic development of the cardiovascular system and such process 
overlaps significantly in the subsequent emergence of tumor angiogenesis that arises 
necessarily as sprouting from pre-existent vessels. 
Primary predominance of dominant action in interactions of integrins with the 
extra-cellular matrix proteins is a critical series of pathway effects that allows cell-matrix 
communication.  In like manner, beta-cadherin and focal adhesion factor allow for 
cell-cell interaction in establishing the vascular sprouting and migration of the activated 
endothelial cells.  Fibroblast growth factor is identified as a candidate cancer biomarker 
in many types of cancer [7]. 
 
INFLAMMATION 
Particular relevant to tumor angiogenesis is the overlap of system pathways as integral to 
inflammation and immune cells.  p38 mitogen-activated protein kinase not only plays a 
central role in induction and regulation of innate and adaptive immunity but also 
promotes tumor invasion, metastasis and angiogenesis [8].  Interleukin-1alpha and 
interleukin 6 are implicated also in the angiogenic switch of developing and expanding 
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masses of tumor cells.  Inflammation induces an extensive series of networks in 
chemotaxis in a manner that operatively determines in multi-faceted dimensional 
angiogenesis in tumors.  In this regard, macrophages and bone marrow mesenchymal 
cells are also implicated in the activation of the vascular endothelial cells that 
subsequently migrate into the matrix.  The proteases of the tumor matrix are constitutive 
and endogenous operants in delineating in a dominant fashion the cooperative overlap of 
inflammatory dynamics and also in hypoxic tumor micro-deposits.  Glycogen Synthase 
Kinase-3beta regulates mTOR/p70S6K1 signaling pathway and exerts growth and 
angiogenesis-inhibitory effects in glioma progression in vivo [9]. 
 
VASCULAR HYPER-PERMEABILITY 
Dominant targeting performance is an integral mechanism in the construction of tumor 
angiogenic networks that include in significant manner hyper-permeable vessels along 
with more mature vascular elements.  Endothelial cell proliferationis influenced by both 
soluble factors and mechanical forces; reduced expression of the mechanosensitive ion 
channel TRPV4 in tumor endothelial cells induces abnormal angiogenesis [10].  
Interactivities are formulas in the interventional behavior of heparin-sulphate 
glycoproteins and extracellular matrix component proteins in the initiation and 
sustainment of pathway induction and activation of various cellular subsets.  The outline 
significance of endogenous stimulation and counter-active inhibitory influences is further 
evidenced by the participation of chemotaxis that is promoted initially as concurrent 
degradation of the vascular basement membrane and activation of the lining endothelial 
cells.  The emergence of endothelial progenitor cells is also a system targeting 
mechanism that appears to promote enhancing influence of mesenchymal bone marrow 
cells. 
Blood perfusion of the tumor vascular bed is evidenced as factor formulation in the 
developing tumor angiogenesis in terms of determined targeting and dynamics of both the 
proliferating and also partly dormant tumor cell fractions within the neoplastic 
micro-deposits.  This vascularization also is instrumental in establishing future 
metastasizing potentialities early in tumorigenesis. 
 
TARGETING STRATEGY 
Inhibition of tumor angiogenesis is hence an attractive targeting strategy in controlling 
tumorigenesis.  Wogonoside, derived from Scutellaria baicalensis Georgi, decreases 
intracellular intracellular Wnt3a, increases expression of GSK-3beta, AXIN, and 
promotes the phosphorylation of beta-catenin for proteasome degradation in breast 
carcinoma [11].  Many degradation products of the vascular basement membrane such as 
endostatin, tumstatin, canstatin appear to exert inhibitory or pro-apoptotic effects not only 
on sprouting endothelial cells but also on related tumor cell bed.  Apoptosis is evidenced 
by VEGF insufficiency in view of an essential role of this growth factor in the survival 
and proliferation of endothelial cells.  In this regard, the hyper-permeability of the 
vascular wall in the tumor cell bed that is induced by VEGF is a central series of 
mechanistic pathways in the expansion of the tumor mass that is inherently hypoxic and 
multifocally ischemic or avascular.  A spheroid-plug model resembles natural tumor 
progression and relies on in vitro formation of tumor spheroids followed by subcutaneous 
injection of single tumor spheroids in matrigel matrix [12]. 
Tumor inflammation is a potent positively inducing mechanism in promoting the 
vascularization of the tumor cell bed in the first instance and has been implicated in the 
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active tumorigenesis that is progressively enhancing in terms of subsequent alignment of 
the neoplastic cells in close apposition to the developing vascularity of the lesion.  
In such terms, angiogenesis is a mediator in the dynamic turnover and proliferation of 
tumor cells that adapt to dynamics of migratory endothelial cell proliferation or possible 
focal apoptosis.  Inflammation-related tumor necrosis factor-alpha induces the tumor 
suppressor protein promyelocytic leukemia to accumulate; resulting nuclear bodies 
mediate cancer cell death and inhibit migration and capillary tube formation by 
endothelial cells [13].  It is with regard to apoptosis of endothelial cells in response to 
sub-maximal doses of chemotherapeutic agents such as cyclophosphamide or vinblastine 
that an especially targeted series of susceptibility phenomena can be created within foci of 
emerging tumorigenesis. 
 
 
2  Concluding Remarks 
Discriminatory criteria as parameters determining the dynamics of angiogenesis and of 
tumor angiogenic switch would recapitulate the embryonic processes involved in 
vasculogenesis as evidenced also by participation of endothelial progenitor cells and also 
of pluripotent cells of bone marrow mesenchymal origin.  The plethora of factors such as 
thrombospondin-1, angiopoietins, urokinase plasminogen activator, multiplicity of 
vascular growth factor sub-types, and the central roles of effect as exerted by integrin 
receptors and of secreted soluble receptor variants attest to a series of paramount 
influences that dictate especially the dynamics of the tumor cell proliferation and of the 
evolving tumorigenesis.  CXCR7, a chemokine receptor, modulates proliferation, 
apoptosis and invasion of papillary thyroid carcinoma, and, in general terms, effects on 
metastasis and angiogenesis [14].  In such terms, inflammatory analogy to the turnover 
and dynamics of influence attest to an angiogenic switch that dominantly incorporates, in 
real measure, the integral malignant transformation process and ensures the sustained 
tumorigenesis phenomenon per se. 
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